HC Wainwright assumed coverage on shares of INmune Bio (NASDAQ:INMB) in a research report released on Wednesday morning, AnalystRatings.com reports. The brokerage issued a buy rating and a $11.50 price objective on the stock.
“We are initiating coverage of INMB with Buy rating and a 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate.”,” HC Wainwright’s analyst wrote.
Separately, Maxim Group reissued a buy rating and issued a $13.00 price objective on shares of INmune Bio in a report on Wednesday, August 14th.
Shares of INMB stock opened at $6.03 on Wednesday. The company has a 50-day moving average price of $8.25. The company has a current ratio of 20.94, a quick ratio of 20.94 and a debt-to-equity ratio of 0.01. INmune Bio has a fifty-two week low of $5.06 and a fifty-two week high of $11.50.
INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.16. Research analysts anticipate that INmune Bio will post -0.72 EPS for the current year.
In related news, Director Scott Juda bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average cost of $6.00 per share, with a total value of $30,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raymond Joseph Tesi bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were bought at an average cost of $6.00 per share, for a total transaction of $60,000.00. The disclosure for this purchase can be found here. Insiders bought 22,000 shares of company stock worth $132,990 over the last three months. Corporate insiders own 67.67% of the company’s stock.
A hedge fund recently raised its stake in INmune Bio stock. BlackRock Inc. raised its stake in shares of INmune Bio Inc (NASDAQ:INMB) by 1,556.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 as of its most recent SEC filing. 0.46% of the stock is owned by institutional investors.
About INmune Bio
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
See Also: Moving Average (MA)
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.